FDA adopts updated ICH Q8/Q9/Q10 Questions & Answers (R5)

The U.S. Food and Drug Administration (FDA) has now published the updated ICH Q8/Q9/Q10 Questions & Answers Document (R5), aligning with the version approved by the ICH Secretariat in October 2024 and published by EMA in February 2025.

The R5 revision updates and streamlines the existing Q&A document by removing outdated text and rephrasing questions and answers in light of practical implementation experience with ICH Q8(R2), Q9(R1), and Q10 across ICH regions. Minor additions address content gaps identified since earlier versions, and editorial changes improve overall readability and consistency.

Key topics covered and clarified in the updated document include Pharmaceutical Development (QbD), Quality Risk Management (QRM), Pharmaceutical Quality Systems (PQS), and - notably - Knowledge Management, with expanded guidance on how Q8, Q9, and Q10 principles interact to support knowledge capture and use across the product lifecycle. The document also addresses GMP inspection practices in the context of the ICH Quality Guidelines, Quality by Design, Real-Time Release Testing (RTRT), and process validation across the lifecycle.

With the FDA's adoption, the R5 document now carries regulatory weight in all major ICH regions, providing manufacturers and marketing authorisation holders with a globally harmonised reference for implementing Q8/Q9/Q10 principles in development, registration, and post-approval activities.